CoChat

Cerebrospinal fluid proteomic study of two bipolar disorder cohorts

Isgren, Anniella, Göteson, Andreas, Holmén-Larsson, Jessica, Pelanis, Aurimantas, Sellgren, Carl, Joas, Erik, Sparding, Timea, Zetterberg, Henrik, Smedler, Erik, Jakobsson, Joel, Landén, Mikael · 2022 · Molecular Psychiatry
Cited by 18

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

The pathophysiology of bipolar disorder remains to be elucidated and there are no diagnostic or prognostic biomarkers for the condition. In this explorative proteomic study, we analyzed 201 proteins in cerebrospinal fluid (CSF) from mood stable bipolar disorder patients and control subjects sampled from two independent cohorts, amounting to a total of 204 patients and 144 controls. We used three Olink Multiplex panels, whereof one specifically targets immune biomarkers, to assess a broad set of CSF protein concentrations. After quality control and removal of proteins with a low detection rate, 105 proteins remained for analyses in relation to case–control status and clinical variables. Only case–control differences that replicated across cohorts were considered. Results adjusted for potential confounders showed that CSF concentrations of growth hormone were lower in bipolar disorder compared with controls in both cohorts. The effect size was larger when the analysis was restricted to bipolar disorder type 1 and controls. We found no indications of immune activation or other aberrations. Growth hormone exerts many effects in the central nervous system and our findings suggest that growth hormone might be implicated in the pathophysiology of bipolar disorder.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41380-022-01724-2

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 36

  1. Harrison PJ, Geddes JR, Tunbridge EM. The Emerging Neurobiology of Bipolar Disorder. Trends Neurosci. 2018;41:18–30. · DOI · Paper page
  2. Bromander S, Anckarsater R, Kristiansson M, Blennow K, Zetterberg H, Anckarsater H, et al. Changes in serum and cerebrospinal fluid cytokines in response to non-neurological surgery: an observational study. J Neuroinflammation. 2012;9:242. · DOI · Paper page
  3. Maier B, Laurer HL, Rose S, Buurman WA, Marzi I. Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study. J Neurotrauma. 2005;22:822–35. · DOI · Paper page
  4. Isgren A, Jakobsson J, Palsson E, Ekman CJ, Johansson AG, Sellgren C, et al. Increased cerebrospinal fluid interleukin-8 in bipolar disorder patients associated with lithium and antipsychotic treatment. Brain Behav Immun. 2015;43:198–204. · DOI
  5. Knorr U, Simonsen AH, Zetterberg H, Blennow K, Hasselbalch SG, Kessing LV. Biomarkers in cerebrospinal fluid of patients with bipolar disorder versus healthy individuals: A systematic review. Eur Neuropsychopharmacol. 2018;28:783–94. · DOI
  6. Göteson A, Isgren A, Jonsson L, Sparding T, Smedler E, Pelanis A, et al. Cerebrospinal fluid proteomics targeted for central nervous system processes in bipolar disorder. Mol Psychiatry. 2021;26:7446–53. · DOI · Paper page
  7. Magioncalda P, Martino M. A unified model of the pathophysiology of bipolar disorder. Mol Psychiatry. 2022;27:202–11. · DOI
  8. Giridharan VV, Sayana P, Pinjari OF, Ahmad N, da Rosa MI, Quevedo J, et al. Postmortem evidence of brain inflammatory markers in bipolar disorder: a systematic review. Mol Psychiatry. 2020;25:94–113. · DOI
  9. Orlovska-Waast S, Kohler-Forsberg O, Brix SW, Nordentoft M, Kondziella D, Krogh J, et al. Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis. Mol Psychiatry. 2019;24:869–87. · DOI · Paper page
  10. Jakobsson J, Zetterberg H, Blennow K, Johan Ekman C, Johansson AG, Landen M. Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder. Neuropsychopharmacology. 2013;38:664–72. · DOI
  11. Ryden E, Thase ME, Straht D, Aberg-Wistedt A, Bejerot S, Landen M. A history of childhood attention-deficit hyperactivity disorder (ADHD) impacts clinical outcome in adult bipolar patients regardless of current ADHD. Acta Psychiatr Scand. 2009;120:239–46. · DOI · Paper page
  12. Isgren A, Sellgren C, Ekman CJ, Holmen-Larsson J, Blennow K, Zetterberg H, et al. Markers of neuroinflammation and neuronal injury in bipolar disorder: Relation to prospective clinical outcomes. Brain Behav Immun. 2017;65:195–201. · DOI
  13. Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 2003;53:1028–42. · DOI · Paper page
  14. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22–33.
  15. Leckman JF, Sholomskas D, Thompson WD, Belanger A, Weissman MM. Best estimate of lifetime psychiatric diagnosis: a methodological study. Arch Gen Psychiatry. 1982;39:879–83. · DOI · Paper page
  16. Roy MA, Lanctot G, Merette C, Cliche D, Fournier JP, Boutin P, et al. Clinical and methodological factors related to reliability of the best-estimate diagnostic procedure. Am J Psychiatry. 1997;154:1726–33. · DOI · Paper page
  17. van den Berg RA, Hoefsloot HC, Westerhuis JA, Smilde AK, van der Werf MJ. Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics. 2006;7:142. · DOI · Paper page
  18. Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest. 1977;37:385–90. · DOI
  19. Göteson A, Isgren A, Sparding T, Holmen-Larsson J, Jakobsson J, Palsson E, et al. A serum proteomic study of two case-control cohorts identifies novel biomarkers for bipolar disorder. Transl Psychiatry. 2022;12:55. · DOI
  20. Butler T, Harvey P, Cardozo L, Zhu YS, Mosa A, Tanzi E, et al. Epilepsy, depression, and growth hormone. Epilepsy Behav. 2019;94:297–300. · DOI
  21. Hampl R, Bicikova M, Sosvorova L. Hormones and the blood-brain barrier. Horm Mol Biol Clin Investig. 2015;21:159–64. · DOI
  22. Lai Z, Roos P, Zhai O, Olsson Y, Fholenhag K, Larsson C, et al. Age-related reduction of human growth hormone-binding sites in the human brain. Brain Res. 1993;621:260–6. · DOI
  23. Schneider HJ, Pagotto U, Stalla GK. Central effects of the somatotropic system. Eur J Endocrinol. 2003;149:377–92. · DOI · Paper page
  24. Steardo L Jr, de Filippis R, Carbone EA, Segura-Garcia C, Verkhratsky A, De Fazio P. Sleep Disturbance in Bipolar Disorder: Neuroglia and Circadian Rhythms. Front Psychiatry. 2019;10:501. · DOI
  25. Takaesu Y. Circadian rhythm in bipolar disorder: A review of the literature. Psychiatry Clin Neurosci. 2018;72:673–82. · DOI · Paper page
  26. Wang W, Duan X, Huang Z, Pan Q, Chen C, Guo L. The GH-IGF-1 Axis in Circadian Rhythm. Front Mol Neurosci. 2021;14:742294. · DOI
  27. Romero CJ, Pine-Twaddell E, Sima DI, Miller RS, He L, Wondisford F, et al. Insulin-like growth factor 1 mediates negative feedback to somatotroph GH expression via POU1F1/CREB binding protein interactions. Mol Cell Biol. 2012;32:4258–69. · DOI
  28. Chen M, Zhang L, Jiang Q. Peripheral IGF-1 in bipolar disorder and major depressive disorder: a systematic review and meta-analysis. Ann Palliat Med. 2020;9:4044–53. · DOI
  29. Scola G, Andreazza AC. The role of neurotrophins in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2015;56:122–8. · DOI
  30. da Silva EG, Pfaffenseller B, Walz J, Stertz L, Fries G, Rosa AR, et al. Peripheral insulin-like growth factor 1 in bipolar disorder. Psychiatry Res. 2017;250:30–34. · DOI
  31. Duval F, Mokrani MC, Erb A, Danila V, Gonzalez Lopera F, Jeanjean L. Dopaminergic, Noradrenergic, Adrenal, and Thyroid Abnormalities in Psychotic and Affective Disorders. Front Psychiatry. 2020;11:533872. · DOI
  32. Harro J, Rimm H, Harro M, Grauberg M, Karelson K, Viru AM. Association of depressiveness with blunted growth hormone response to maximal physical exercise in young healthy men. Psychoneuroendocrinology. 1999;24:505–17. · DOI
  33. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry. 2000;61:742–9. · DOI · Paper page
  34. Gründer G, Wetzel H, Schlösser R, Anghelescu I, Hillert A, Lange K, et al. Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiatry. 1999;45:89–97. · DOI
  35. Jakobsson J, Bjerke M, Sahebi S, Isgren A, Ekman CJ, Sellgren C, et al. Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. J Psychiatry Neurosci. 2015;40:250–8. · DOI · Paper page
  36. Enroth S, Hallmans G, Grankvist K, Gyllensten U. Effects of Long-Term Storage Time and Original Sampling Month on Biobank Plasma Protein Concentrations. EBioMedicine. 2016;12:309–14. · DOI · Paper page

Metadata

Authors
Isgren, A., Göteson, A., Holmén-Larsson, J., Pelanis, A., Sellgren, C., Joas, E., Sparding, T., Zetterberg, H., Smedler, E., Jakobsson, J., & Landén, M.
Venue
Molecular Psychiatry
Published
2022-08-19
Volume
27
Issue
11
Pages
4568-4574
ISSN
  • 1359-4184
  • 1476-5578
Cited by
18
References
7
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cerebrospinal fluid proteomic study of two bipolar disorder cohorts. https://app.cochat.ai/papers/10.1038/s41380-022-01724-2
The paper
Isgren, A., Göteson, A., Holmén-Larsson, J., Pelanis, A., Sellgren, C., Joas, E., Sparding, T., Zetterberg, H., Smedler, E., Jakobsson, J., & Landén, M. (2022). Cerebrospinal fluid proteomic study of two bipolar disorder cohorts. Molecular Psychiatry. https://doi.org/10.1038/s41380-022-01724-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.